<code id='06B851E8E3'></code><style id='06B851E8E3'></style>
    • <acronym id='06B851E8E3'></acronym>
      <center id='06B851E8E3'><center id='06B851E8E3'><tfoot id='06B851E8E3'></tfoot></center><abbr id='06B851E8E3'><dir id='06B851E8E3'><tfoot id='06B851E8E3'></tfoot><noframes id='06B851E8E3'>

    • <optgroup id='06B851E8E3'><strike id='06B851E8E3'><sup id='06B851E8E3'></sup></strike><code id='06B851E8E3'></code></optgroup>
        1. <b id='06B851E8E3'><label id='06B851E8E3'><select id='06B851E8E3'><dt id='06B851E8E3'><span id='06B851E8E3'></span></dt></select></label></b><u id='06B851E8E3'></u>
          <i id='06B851E8E3'><strike id='06B851E8E3'><tt id='06B851E8E3'><pre id='06B851E8E3'></pre></tt></strike></i>

          Home / comprehensive / knowledge

          knowledge


          knowledge

          author:leisure time    Page View:16
          Adobe

          Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity.

          In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

          advertisement

          The new analysis was conducted on 16 children diagnosed with a rare form of epilepsy called Dravet syndrome. Last November, in six patients, the drug showed a median 55% reduction in seizure activity.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In